Does Wegovy stop the pill working — what the guidance actually says

Why this question comes up at all

GLP-1 medicines like semaglutide slow the rate at which food (and anything else you swallow) moves through your stomach. In pharmacology, that is called delayed gastric emptying, and it raises a reasonable question: if a tablet spends longer in your stomach before reaching the small intestine, does that change how much of it gets absorbed?

For oral contraceptives, the concern is that delayed absorption could lower the effective blood level of the hormones, potentially reducing protection. It is a mechanistically plausible worry, and it is why this question appears in NHS guidance at all. The NHS semaglutide medicines page addresses contraception specifically, so this is not a gap in the official record, it has been considered.

The short answer from the current evidence is that the concern is real for tirzepatide (Mounjaro), where NHS guidance recommends adding a non-oral backup method for the first four weeks of treatment and for four weeks after each dose increase. For semaglutide, the guidance is different: no equivalent evidence of reduced pill effectiveness has been identified. That distinction matters, and it is not always clearly communicated when people switch between medicines or read general GLP-1 advice online. If you have seen conflicting information and are wondering does Wegovy effect the pill, that page works through why the wording varies across different sources.

What the guidance says about Wegovy specifically

NHS England's guidance, and NHS Inform Scotland's published advice, both draw the same line: semaglutide does not carry the same cautionary language about oral contraceptive absorption that applies to tirzepatide. The biological reason likely relates to how each medicine interacts with gastric motility, semaglutide's effect on gastric emptying is present but appears less pronounced in ways that affect orally absorbed hormonal contraceptives.

That said, the MHRA's broader position on GLP-1 medicines is that effective contraception should be used while on treatment, and for a period after stopping, before trying to conceive. This is primarily a pregnancy-safety recommendation rather than a concern about pill failure specifically. Semaglutide is not recommended during pregnancy, and an unintended pregnancy on treatment would be a clinical concern, so using reliable contraception remains important regardless of whether the pill's absorption is affected. If you want a detailed look at how Wegovy affects the pill, that page covers the absorption question and the pregnancy-safety angle together.

If you are considering the newer oral format, the Wegovy tablet is itself taken orally once daily on an empty stomach. That introduces its own absorption conditions (the 30-minute fasting window before food or other medicines) and it is worth discussing with a prescriber whether the timing of your contraceptive pill needs to be considered alongside it.

How this compares with Mounjaro's contraception advice

The contrast with tirzepatide is useful context. For Mounjaro, NHS guidance is explicit: women using combined oral contraceptives should add a non-oral method (condoms, for example) for the first four weeks of treatment and for four weeks after every dose increase. NHS England also flags that transdermal HRT (patches or gels) is worth considering over oral HRT for the same absorption reason.

No comparable instruction exists in current NHS guidance for semaglutide. That is not a loophole or an oversight; it reflects the current state of the evidence. Clinical guidance does evolve, though, and this is precisely the kind of detail a prescriber checks at each review. At nume, every repeat order is clinically re-reviewed before anything is dispensed, a named clinician looks at your record, not an automated system. For more on how the service works, the about us page covers the clinical infrastructure behind it.

It is also worth knowing that Wegovy carries a Black Triangle (▼) designation from the MHRA, meaning additional post-market monitoring is in place. New safety data, including data on interactions with other medicines, feeds into updated guidance as the evidence base grows. For anyone who wants to report a suspected effect, the MHRA Yellow Card scheme is the right channel.

What to do if you are unsure about your contraception

The practical advice is straightforward. If you are on semaglutide (Wegovy injection or the Wegovy tablet) and using the contraceptive pill, the current NHS position does not require you to add a backup method as a matter of routine, unlike tirzepatide, where that instruction is clear. But if you have any doubt, or if your prescriber or GP has flagged something specific to your situation, act on that advice rather than general guidance online.

A good starting point is the question of timing, especially if you are moving to the oral tablet format. The oral semaglutide evidence page covers what the OASIS 4 trial found, and for a broader view of how the tablet compares with the injection, the semaglutide tablets overview is a useful reference. For anyone asking more broadly whether semaglutide pills work for weight loss, that page sets out the clinical trial data behind the oral formulation. If you are thinking about starting treatment and want to discuss your contraception as part of a clinical assessment, the free consultation through weight-loss treatments is the place to begin, your consultation is reviewed the same day by a GPhC-registered prescriber who can take your full picture into account.

One practical note: if you do start Wegovy and are approved, your pen arrives via DPD the next working day in plain, unbranded packaging, nothing on the outside indicates what is inside. Your prescriber will have already reviewed your contraception history as part of that process.